Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mind Medicine (MNMD)
NASDAQ:MNMD
Holding MNMD?
Track your performance easily
MNMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.37 - $12.22
Previous Close$7.02
Volume1.77M
Average Volume (3M)1.17M
Market Cap
$514.42M
Enterprise Value$276.28M
Total Cash (Recent Filing)$252.33M
Total Debt (Recent Filing)$14.19M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Apr 08, 2025EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.08
Shares Outstanding81,430,000
10 Day Avg. Volume1,155,354
30 Day Avg. Volume1,169,932
Standard Deviation1.35
R-Squared0.07
Alpha0.29
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.95
Forecast
1Y Price Target
$24.29Price Target Upside239.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Mind Medicine News
PremiumCompany Announcements
MindMed Begins Phase 3 LSD Study for Anxiety
PremiumCompany Announcements
MindMed Appoints New Chief to Boost Drug ApprovalsOwnership Overview
2.53% Insiders
5.50% Mutual Funds
42.51% Other Institutional Investors
41.05% Public Companies and Individual Investors
MNMD FAQ
What was Mind Medicine’s price range in the past 12 months?
Mind Medicine lowest stock price was $3.37 and its highest was $12.22 in the past 12 months.
What is Mind Medicine’s market cap?
Currently, no data Available
When is Mind Medicine’s upcoming earnings report date?
Mind Medicine’s upcoming earnings report date is Apr 08, 2025 which is in 107 days.
How were Mind Medicine’s earnings last quarter?
Mind Medicine released its earnings results on Nov 07, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.277 by $0.097.
Is Mind Medicine overvalued?
According to Wall Street analysts Mind Medicine’s price is currently Undervalued.
Does Mind Medicine pay dividends?
Mind Medicine does not currently pay dividends.
What is Mind Medicine’s EPS estimate?
Mind Medicine’s EPS estimate is -$0.29.
How many shares outstanding does Mind Medicine have?
Mind Medicine has 73,331,690 shares outstanding.
What happened to Mind Medicine’s price movement after its last earnings report?
Mind Medicine reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.277. Following the earnings report the stock price went up 12.899%.
Which hedge fund is a major shareholder of Mind Medicine?
Currently, no hedge funds are holding shares in MNMD
---
Mind Medicine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.29 (239.25% Upside)
$24.29 (239.25% Upside)
Blogger Sentiment
Bullish
MNMD Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $17.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
94.86%
12-Months-Change
Fundamentals
Return on Equity
-54.61%
Trailing 12-Months
Asset Growth
125.91%
Trailing 12-Months
Company Description
Mind Medicine
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.
---
MNMD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted MindMed's strong financial position and progress towards Phase III trials, while also acknowledging rising R&D expenses and a net loss. The sentiment leans towards positive due to the company's strong cash reserves and clear roadmap for advancing clinical trials.Read More>---
MNMD Stock 12 Month Forecast
Average Price Target
$24.29
▲(239.25% Upside)
Technical Analysis
Best Analysts Covering MNMD
1 Year
1 Year Success Rate
11/21 ratings generated profit
1 Year Average Return
+31.35%
reiterated a buy rating last month
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +31.35% per trade.
---